On the other hand, the immunohistochemical AR status in primary breast carcinoma tissues correlates with longer disease-free and overall survival in breast cancer patients receiving endocrine therapies (SERM: 71.8%; SERM followed by AI: 25.2%; AI: 2.9%) (Park et al. 2012). The gene discussed is AR; the disease is breast cancer.